This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis
Blood Cancer Journal Open Access 02 October 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
Isobe M, Emanuel BS, Givol D, Oren M, Croce CM . Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986; 320: 84–85.
Pietsch EC, Sykes SM, McMahon SB, Murphy ME . The p53 family and programmed cell death. Oncogene 2008; 27: 6507–6521.
Levine AJ . P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331.
Wickremasinghe RG, Prentice AG, Steele AJ . p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia 2011; 25: 1400–1417.
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458–1461.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.
Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012–6018.
Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399–404.
Muthusamy N, Breidenbach H, Andritsos L, Flynn J, Jones J, Ramanunni A et al. Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. Cancer Genet 2011; 204: 77–83.
Heerema NA, Byrd JC, Dal Cin PS, Dell'Aquila ML, Koduru PR, Aviram A et al. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet 2010; 203: 134–140.
Shaffer L, Slovak M, Campbell L ISCN 2009: an international system for human cytogentetic nomenclature 2009.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.
van Buuren S . Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007; 16: 219–242.
Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM et al. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 2011; 25: 1444–1451.
Acknowledgements
This work supported by Four Winds Foundation, D Warren Brown Foundation, Mr and Mrs Michael Thomas, Harry Mangurian Foundation, P50 CA140158, R01 CA177292, P01 CA095426, Leukemia and Lymphoma Society, Conquer Cancer Foundation, and ASH Scholar Award.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
All authors critically revised the manuscript and approved the final submitted version. DS and AR acquired, analyzed and interpreted data and drafted the manuscript. JJ, JW, KM, SJ, LA, JF, MG, GL, AJ, NM and NH contributed to acquisition of data. NH acquired and analyzed cytogenetic data. DS and JB developed the concept for the study.
Rights and permissions
About this article
Cite this article
Stephens, D., Ruppert, A., Jones, J. et al. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia 28, 1365–1368 (2014). https://doi.org/10.1038/leu.2014.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.42
This article is cited by
-
Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis
Blood Cancer Journal (2015)
-
Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?
Current Hematologic Malignancy Reports (2015)